Omega Diagnostics Group (LON:ODX) Receives “Corporate” Rating from FinnCap

Omega Diagnostics Group (LON:ODX)‘s stock had its “corporate” rating reissued by investment analysts at FinnCap in a research report issued on Tuesday, ThisIsMoney.Co.Uk reports.

Omega Diagnostics Group stock opened at GBX 33 ($0.41) on Tuesday. The stock has a market cap of $52.19 million and a price-to-earnings ratio of -110.00. The company has a debt-to-equity ratio of 18.26, a current ratio of 1.27 and a quick ratio of 0.86. Omega Diagnostics Group has a 1 year low of GBX 6 ($0.07) and a 1 year high of GBX 91.50 ($1.13). The firm has a 50-day moving average of GBX 52.63 and a two-hundred day moving average of GBX 29.72.

About Omega Diagnostics Group

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases.

Featured Article: The role of implied volatility with call option volume

Receive News & Ratings for Omega Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.